clinical trial · NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute·phase1·completed·n = 14
Non Hodgkin LymphomaHodgkin LymphomaMyelomaLymphocytic LeukemiaBMS-986345Duvelisib
brief summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
started
Nov 18, 2021
primary completion
Jan 2, 2024
completion
Apr 24, 2024
last updated
Dec 4, 2025
official title
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol